Drug Trial Radar · NCT05795816
Effectiveness of Testofen Compared to Placebo on Long COVID Symptoms
Last checked: Nov 19, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Oct 25, 2023
Primary completion
Jan 30, 2025
Study completion Jan 31, 2025
Sponsor
- Lead sponsor
- RDC Clinical Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed Testofen (a specialised extract of Trigonella foenum-graecum (Fenugreek) seed) compared to placebo on post COVID-19 symptoms in otherwise healthy participants 18 years and over.
Conditions
- Long Covid19
Interventions
TestofenDrug
Twice daily dose of 1 capsule (300mg per capsule Testofen)
Microcrystalline celluloseDrug
Twice daily dose of 1 capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Energy and FatigueTime frame: Baseline, week 4, week 8 and week 12
- Change in Energy and FatigueTime frame: Baseline, week 4, week 8 and week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
RDC Clinical Pty Ltd
Brisbane, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.